Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Daxor Corp (NQ: DXR )

8.900 UNCHANGED
Streaming Delayed Price Updated: 2:27 PM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 8.900
Bid (Size) 8.630 (1)
Ask (Size) 13.72 (1)
Prev. Close 8.900
Today's Range 8.900 - 8.900
52wk Range 8.550 - 14.55
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
From Daxor Corporation
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga

Performance

YTD
-1.11%
-1.11%
1 Month
-5.52%
-5.52%
3 Month
-33.29%
-33.29%
6 Month
-36.01%
-36.01%
1 Year
-21.10%
-21.10%

More News

Read More
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
Via Benzinga
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
From Daxor Corporation
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
From Daxor Corporation
Via Globe NewsWire
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs
From Daxor Corporation
Via Globe NewsWire
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
From Daxor Corporation
Via Globe NewsWire
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
From Daxor Corporation
Via Globe NewsWire
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
From Daxor Corporation
Via Globe NewsWire
DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
From Daxor Corporation
Via Globe NewsWire
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
From Daxor Corporation
Via Globe NewsWire
New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
From Daxor Corporation
Via Globe NewsWire
New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care
From Daxor Corporation
Via Globe NewsWire
New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures
From Daxor Corporation
Via Globe NewsWire
Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
From Daxor Corporation
Via Globe NewsWire
32 Stocks Moving in Friday's Pre-Market Session
Via Benzinga
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
From MicroCap Rodeo
Via AccessWire
64 Biggest Movers From Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.